Mental Health Clinical Trials Market Size, Report 2023-2032
The global mental health clinical trials market size was estimated at around USD 2.76 billion in 2022 and it is projected to hit around USD 6.15 billion by 2032, growing at a CAGR of 8.35% from 2023 to 2032. The mental health clinical trials market in the United States was accounted for USD 1.3 billion in 2022.
Key Pointers
Report Scope of the Mental Health Clinical Trials Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 50.34% |
| CAGR of Asia Pacific | 8.87% |
| Revenue Forecast by 2032 | USD 6.15 billion |
| Growth rate from 2023 to 2032 | CAGR of 8.35% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | ICON Plc, Eli Lilly Company, Caidya, Syneous Health, Novo Nordisk, Pharmaceutical Product Development, LLC, Parexel International Corporation, Corcept, Labcorp Drug Development, and IQVIA. |
Mental health has become a major area of concern globally, and the need for effective treatments and therapies has become more pressing than ever. Due to the rising incidence of mental diseases like bipolar disorder, anxiety, and depression, mental health has become a major global problem. The market for mental health clinical trials has expanded as a result of the rising prevalence of these disorders and the increased demand for effective treatments and cures.
Also, the industry has expanded as a result of governments and private groups investing more money in clinical trials and mental health research. The need for effective therapies has grown as a result of the increased knowledge and openness surrounding mental health. Additionally, new avenues for mental health therapies have been made possible by technical developments like telemedicine and digital pharmaceuticals. The market for mental health clinical trials is expanding as a result of these developments, which have made it possible for patients to receive more creative and individualized therapies.
Due to their strong dedication to research and development, which is fostering the creation of novel therapies for mental health diseases, the pharmaceutical and biopharmaceutical market has dominated the market for mental health clinical trials. Clinical trials are being substantially funded by pharmaceutical and biopharmaceutical companies in order to evaluate the efficacy and safety of their products before regulatory agencies like the FDA approve them. In recent years, several pharmaceutical and biopharmaceutical companies have made significant advancements in developing mental health treatments.
For instance, in 2019, U.S. FDA approved Spravato, a nasal spray to be used for the treatment of depression in adults. The drug contains a chemical called Esketamine, which works differently from traditional antidepressants and can produce rapid results in patients. The market for mental health clinical trials is anticipated to expand as long as pharmaceutical and biopharmaceutical businesses continue to make research and development investments. Their emphasis on the creation of efficient cures and treatments for mental health issues has the potential to greatly enhance the lives of people with these conditions.
Phase Segment Insights
The phase I segment is anticipated to witness the fastest CAGR of 8.76% during the analysis period. Phase I studies evaluates the pharmacokinetics and tolerability of molecules along with assessing the safety of a drug/biologic. It determines the effect of a drug on humans, including how it is absorbed, metabolized, and excreted. It also studies the side effects of a drug compound in case of amplified dosage levels. Phase I includes 20-100 healthy people or volunteers with the disease. An increasing number of companies focusing on investing in mental health research is one of the major factors supporting the lucrative CAGR of the segment.
The phase 3 clinical trials segment is the most dominating phase in the market with a revenue share of 31.04% in 2022 as it involves testing a treatment on a large patient population in multiple centers to determine its effectiveness, safety, and side effects. For a new medicine to be approved and made available commercially, Phase 3 trial findings are essential. For instance, the U.S. FDA recently approved the medication Brexanolone after a recent Phase 3 clinical research showed that it was helpful in treating postpartum depression in women. The success of treatment on the market is greatly influenced by the outcomes of phase 3 clinical trials, which also require a sizeable time and financial investment.
Study Design Segment Insights
Since there is a demand for efficient interventions for mental health illnesses, the study design segment has the highest revenue share of 64.28% in 2022. This segment of the mental health clinical trials market analysis is an important consideration when conducting research. Interventional studies involve an active intervention, such as administering a drug or therapy, to assess its effectiveness. For instance, the US FDA recently approved the medication Esketamine. After recent interventional research, it was shown to be beneficial in treating depression that has resisted treatment.
On the other side, observational studies are intended to observe and gather data without any kind of intervention. New targets for intervention can also be found through observational studies. For instance, a recent observational study identified a link between childhood trauma and a higher risk of depression and anxiety disorders in adulthood. This discovery can guide the creation of therapies that will either prevent or treat certain illnesses. The segment is anticipated to register the fastest CAGR of 8.6% during the analysis period.
Disorder Segment Insights
The anxiety disorder segment accounted for the highest CAGR of 8.85% from 2023 to 2032. Clinical trials for anxiety disorders often evaluate new medications or therapies to lessen symptoms, including excessive worry, fear, and panic attacks. For instance, a recent clinical trial by Sage Therapeutics to evaluate the efficacy of SAGE-217, a novel medication, in treating individuals with generalized anxiety disorder showed encouraging results.
Depression holds the highest percent share owing to factors such as the increasing prevalence of the condition in the past few years, growing awareness about the condition in developing economies, and increasing research and development activities with an aim to develop novel therapeutics in treating the ailment. For instance, the US FDA recently approved the antidepressant medicine Esketamine after a recent clinical trial by Johnson & Johnson's subsidiary, Janssen Pharmaceuticals, which examined its efficacy in treating patients with depression who had failed to respond to other treatments.
Generally, mental health diseases such as anxiety disorders and depression are common and need effective treatments. With clinical trials evaluating the efficacy of novel medications and therapies, the market for mental health clinical trials is essential in the development of new treatments for these conditions. It is believed that as research into mental health issues progresses, new treatments may appear that can enhance the lives of the millions of individuals affected by these conditions.
Sponsor Segment Insights
The pharmaceutical and biopharmaceutical firms dominated the market in 2022 with a revenue share of 39.66%, due to their significant investments in the creation of novel medicines for mental health diseases. These businesses are equipped to carry out extensive clinical research and launch novel medications. For instance, Janssen Pharmaceuticals, a division of Johnson & Johnson, carried out numerous clinical trials to create the antidepressant medication Esketamine, which received U.S. FDA approval in 2019.
Government agencies are also important sponsors of mental health clinical trials. However, this segment is at a stable CAGR of 8.51% as government agencies face budget constraints and may have limited resources to invest in clinical trials. Nonetheless, government agencies play a crucial role in funding and conducting research on mental health disorders, which can lead to the development of new treatments and interventions. For example, the NIH is funding multiple clinical trials through it’s HEAL initiative to address the opioid epidemic in the United States. Governmental agencies also play a critical role in funding and carrying out research, even though pharmaceutical and biopharmaceutical companies are the main power in the market for mental health clinical trials. Collaboration between these institutions has the potential to enhance the lives of millions of people globally and pave the way for the creation of efficient therapies for mental health illnesses.
Regional Insight
Asia Pacific will have the highest CAGR of 8.87% during the analysis period, due to the region's quick rise in the frequency of mental health issues and rising investment in clinical research. The expansion of the mental health clinical trials market in this area is being fueled by the rising usage of cutting-edge technologies and the availability of a sizable patient pool. For instance, the Shanghai Mental Health Center recently investigated the efficacy of transcranial direct current stimulation (TDCS) in treating patients with major depressive disorder in China, and the results were encouraging.
North America is the most dominating market in the mental health clinical trials industry with a revenue share of 50.34% in 2022, as the region has a well-established healthcare infrastructure, a favourable regulatory environment, and a high prevalence of mental health disorders. The presence of major pharmaceutical and biopharmaceutical companies in the region, such as Pfizer, Johnson & Johnson, and Eli Lilly, further drive the growth of the market. For example, a recent clinical trial conducted by Pfizer tested the effectiveness of a new drug called PF-06438179 in treating patients with schizophrenia, leading to promising results and paving the way for further development.
The market for clinical trials in the field of mental health is geographically diversified, with each location having certain traits and laws that affect the design and conduct of clinical trials. Although North America still dominates the market, the Asia Pacific area is expanding quickly and is anticipated to do so for the foreseeable future. Collaboration between academics, physicians, and organizations from all around the world is necessary to discover effective therapies for mental health illnesses.
Mental Health Clinical Trials Market Segmentations:
By Phase
By Study Design
By Sponsor
By Disorder
By Regional
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers